ISRG Stock Recent News
ISRG LATEST HEADLINES
Investors have been looking at robotics companies for several decades. But artificial intelligence (AI) is taking robotics beyond basic automation by bringing more precision, flexibility, and adaptability into the sector.
The use of robotics in surgery is on the rise. The market was valued at $800 million in 2015, and has since risen to over $3 billion.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.
Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies.
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Intuitive Surgical's da Vinci system is driving strong global growth, with 17% YoY procedure growth and expanding adoption across hospitals and specialties. Recurring revenue streams from system sales, procedures, and services support robust financials, including 21% YoY revenue growth and 68% gross margins. The company's expanding installed base and accelerating procedure growth position it for continued earnings stability and long-term shareholder returns.
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
Investing in stocks is both accessible to the general public and likely to yield strong returns over the long term. That's what makes it one of the best ways to increase your wealth.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.